NCT03967886

Clinical Trial to Assess the Efficacy and Safety of YYD601 in NERD Patients

A Randomized, Double-blind, Placebo-controlled, Multi-centers Clinical Trial to Assess the Efficacy and Safety of YYD601 in NERD Patients (Phase3).

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 170 (actual)
• Sponsor: Yooyoung Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 20 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Clinical Trial to Assess the Efficacy and Safety of YYD601 in NERD Patients

Detailed description

This Phase 3 Clinical Trial is Designed as Randomized, Double-blind, Placebo-controlled, Multi-centers Clinical Trial to Assess the Efficacy and Safety of YYD601 in NERD Patients (Phase3).

Conditions

• Non-erosive Reflux Disease

Interventions

Type	Name	Description
DRUG	YYD601 20mg	Patients should take drugs an hour before breakfast.
DRUG	Nexium 20mg	Patients should take drugs an hour before breakfast.
DRUG	Placebos	The placebo YYD601 is made from microcrystalline cellulose covered with hard shell. The placebo Nexium is made from microcrystalline cellulose, Crospovidone, Magnesiumstearat and other ingredients.

Timeline

• Start date: 2019-04-10
• Primary completion: 2019-12-20
• Completion: 2020-05-27
• First posted: 2019-05-30
• Last updated: 2021-05-11

Locations

1 site across 1 country: South Korea